of specific cytotoxic T cells. There have been several trials of combined chemoimmunotherapy in an attempt to improve response rates and the duration of responses by using potential additive or synergistic interactions. Early reports of the addition of IFN-a to DTIC suggested improved response rates and diseasefree survivals, although this was not borne out by subsequent randomized trials (Falkson et al, 1991; Thomson et al, 1993; Bajetta et al, 1994) . The addition of IL-2 to chemotherapy has been disappointing in reported phase II trials with response rates of 24-41% (Flaherty et al, 1993) . Two trials of intensive regimens using more than one chemotherapy agent with both IL-2 (given as i.v. infusion) and subcutaneous IFN-cx have claimed much improved overall response rates of 57% (Richards et al, 1992; Legha et al, 1993) . However, toxicities were significant with severe myelosuppression and a high frequency of systemic sideeffects due to the addition of IL-2 and IEN-a (fever, fatigue, nausea and vomiting, oedema, hypotension and dermatitis).
Although these recent studies have suggested that sequential chemoimmunotherapy may improve response rates and produce some prolonged complete remissions, there are no randomized trials comparing chemotherapy alone with chemotherapy and IL-2/IFNa. Inherent bias in the selection of patients for intensive chemoimmunotherapy schedules may explain the high response rates reported in phase II studies (Richards et al, 1992; Legha et al, 1993) . There are published data on the improved toxicity of subcutaneous IL-2 and IFN-ax in patients with renal cell cancer, with response rates similar to those reported for high-dose intravenous IL-2 (Buter et al, 1993; Atzpodien et al, 1995) . In addition, there are published phase II reports of responses in patients with advanced melanoma treated with subcutaneous IL-2 and IFN-a as sole therapy (Atzpodien et al, 1990; Castello et al, 1993) . The principal aim of the study was to use a subcutaneous schedule for IL-2 and IFN-ax in combination with chemotherapy to see if the improved response rates reported for chemotherapy with intravenous IL-2 in melanoma could be demonstrated in patients with advanced melanoma in a randomized trial using a better tolerated, yet immunologically active, biotherapy regimen. Although this moderate dose and schedule of IL-2 and IFN has not been formally studied in melanoma, the tolerability and activity of this regimen in renal cell cancer made it reasonable to see whether there was enhanced activity when combined with chemotherapy, provided this was done in the context of a randomized study. The dose of IL-2 used was based on experience of the immunological changes that occur with IL-2 given subcutaneously, using a schedule that was previously well tolerated (Atzpodien et al, 1993; Castello et al, 1993) . Similarly, the dose of interferon has been used in a number of interferon-DTIC studies (Falkson et al, 1991) .
PATIENTS AND METHODS Patients
Sixty-five patients (aged between 18 and 70 years) with metastatic melanoma or locally recurrent tumour that could not be controlled by surgery were eligible for the study. Patients were required to have a good Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, life expectancy > 3 months and have received no more than one previous systemic chemotherapy treatment. Prior radiotherapy or biological therapy was allowed, but all previous treatments were stopped at least 4 weeks before entry. Patients with cerebral metastases were excluded (although routine computerized tomography (CT) headscan screening in asymptomatic patients was not perforned). All eligible patients who gave written informed consent were registered into the study and randomized centrally (Clinical Trials Office, Institute of Cancer Research, Sutton).
Drugs
All patients received BCDT (cycle repeated every 28 days) as follows: day 1, BCNU (carmustine) 100 mg m-2 i.v. (administered on alternate courses); days 1-3, cisplatin 25 mg m-2 i.v. dacarbazine 220 mg m-2 i.v. and tamoxifen 40 mg orally.
Those patients who were randomized to receive biochemotherapy received IL-2/IFN-a in addition, as follows: day -2, IL-2 18 x 106 t.d.s. s.c.; days -1 and 0, IL-2 9 x 106 b.d. s.c.; days 1-3, interferon alpha 9 MU daily s.c. 30 min before chemotherapy.
Response and duration of therapy
All patients received two cycles of treatment, unless they had obvious clinical evidence of disease progression before this. Numbers in parentheses are percentages.
(age range 21-50 years) and are expressed as two significant differences (s.d.) from the mean. The monoclonal antibody required (10 gl) was added to 100 pl of whole blood (EDTA) and vortexed. After 10 min at room temperature, the red blood cells were lysed and the sample buffered and fixed using the Coulter GPrep system. The cell surface markers were then analysed as a Coulter Epics Profile II flow cytometer. A model T-540 haematology analyser (Coulter) was used to assess total white blood cell and lymphocyte counts; the reference ranges were 4.8-10.8 x 109 1-1 and 1.2-3.4 x 109 1-' respectively.
Statistical methods
The major end point in the study was response rate. The study was a two-arm randomized trial with a minimum of 30 patients in each arm. It was designed as a phase II trial so that there was an 85% chance of recommending that a phase III study be undertaken if the difference in response rate was 20% or more favouring the biological therapy. A large false-positive error rate (30%) was considered acceptable because a phase III trial would detect such an error, and because it was felt that large differences in response rate would be required to compensate for increased toxicity due to the addition of biological response modifiers. Progression-free and overall survival curves were constructed using the Kaplan-Meier method and analysed by the log-rank method. The baseline peripheral blood lymphocyte subset values were analysed between the two groups using the non-parametric Mann-Whitney test. The changes in immunological parameters after subcutaneous IL-2 were analysed using the Wilcoxon signedrank test. Table 1 . The two groups were well balanced for age, sex, performance status, prior therapies and sites of measurable metastatic disease. The majority of patients in both groups had visceral involvement with disease sites other than skin and/or lymph nodes (88% and 96% respectively). All patients were evaluable for toxicity and response. The number of received courses of treatment was the same between the two groups (median number of courses 2.9 and 3.0 respectively). There was no difference in the objective response rate (CR + PR) between patients treated with BCDT + IL-2 + IFNa (23%, 95% confidence interval 10-40%) and those treated with BCDT alone (27%, 95% confidence interval 12-46%) ( Table 2) . One patient who received biochemotherapy attained a complete response in multiple skin nodules, which was maintained for 10 months. There were no complete responses in those who received BCDT alone. Partial responses were obtained in 7 out of 35 (20%) combined biochemotherapy and 8 out of 30 (27%) chemotherapyalone treated patients. The median duration of these objective responses was similar: 2.8 months (range 1.1-10.7) and 2.5 months (range 0.75-6.6), respectively, for responding patients in both groups. The median time to attain best response was 8 weeks, and all patients attained their best response by three cycles of treatment.
Stabilization of disease (i.e. no change in tumour measurements after at least two courses of treatment) was seen in ten (29%) combined biochemotherapy and six (20%) chemotherapy-alone treated patients, and in these the median time to disease progression was similar (4.8 and 4.75 months respectively). For those with clinical evidence of disease progression during treatment, the median time to disease progression was short: 1.1 and 1.5 months for combined biochemotherapy and chemotherapy-alone patients respectively. Overall, there was no difference in progression-free survival ( Figure 1 ) and overall survival (Figure 2 ) between patients treated with combined chemoimmunotherapy and chemotherapy alone. The median survival was 5 months (range 1.2-26) for patients treated with BCDT + IL-2 + IFN-a, and 5.5 months (range 0.5-20.5) for those treated with BCDT alone.
The sites of measurable disease are shown in Table 3 . The most frequent responses were seen in lung, lymph node and cutaneous sites of disease. A higher percentage of lymph node and lung sites responded to chemotherapy alone compared with combined biochemotherapy, but these differences were not statistically significant. There was no difference in the time to relapse for each site between the two treatment groups. Four patients in each group relapsed during treatment with brain metastases. We assessed whether the 3-day subcutaneous IL-2 schedule used in this study before chemotherapy was associated with immune activation. Before any treatment, patients in both arms of the study (n = 23, BCDT/IL-2/IFNa and n = 17, BCDT alone) had similar numbers of peripheral blood lymphocyte subsets (Table 4) .
Three days of subcutaneous IL-2 resulted in a significant suppression of the total lymphocyte count in 14 patients randomized to receive IL-2 before chemotherapy: 1.8 (± 0.2, standard error of the mean) x 109 1-' before IL-2, falling to 0.8 (± 0.1) x 109 1-1 after IL-2, P = 0.001 (Wilcoxon signed-rank test). Despite the significant fall in the peripheral lymphocyte count induced by IL-2, there was a slight but significant rise in the percentage of NK cells and activated T-cell subsets (Table 5 ). The percentage of NK cells increased to 19.8 ± 2.8% after IL-2 from 13.5 ± 2.1% before IL-2 (P = 0.048, Wilcoxon signed-rank test), and the percentage of activated T cells rose to 13.6 ± 1.5% after IL-2 from 8.1 ± 0.9% before IL-2 (P = 0.004). Overall, the consequence of this shift in percentage distribution was a lack of any change in the total cell count for these subsets despite the overall lymphopenia (Table 5 ). There was no change in the percentage of PBLs of the CD4 and CD8 phenotypes, and these absolute cell counts fell.
There was a marked difference in the pattern of treatmentrelated toxicity between the BCDT + IL-2 + IFN-a-treated patients compared with those who received BCDT alone (Table 5) . Haematological toxicity was generally mild, but with combined biochemotherapy there was a statistically significant higher incidence of grade 3-4 thrombocytopenia, 37% vs 13% (P = 0.03) (Table 6 ). Severe nausea and vomiting were also more frequent patients treated with biochemotherapy, as was hepatic disturbance (Table 6 ). Severe fatigue and flu-like symptoms together with breathlessness were also more common in those treated with IL-2 + IFN-a in addition to chemotherapy, although none of these other differences were statistically significant. (1998) 77(8) (Falkson et al, 1991) , although this was not confirmed subsequently in two larger randomized trials (Thomson et al, 1993; Bajetta et al, 1994) . Interleukin 2 (IL-2) enhances the cellular immune response by stimulating natural killer cells and specific cytotoxic T-cell expansion. In phase II trials, the addition of intravenous IL-2 to DTIC gave response rates of 22-26% (Dillman et al, 1990; Flaherty et al, 1990; Stoter et al, 1991) . Although these results are marginally better than those obtained with DTIC alone, the potential benefit of IL-2 with single-agent chemotherapy has not been studied prospectively in randomized phase III trials. Biological therapy with combined IEN-a and IL-2 may result in synergistic interactions, with enhanced antigen presentation due to IFN-a-mediated up-regulation of class 1 MHC molecules and consequent improvement in tumour recognition by IL-2-stimulated cytotoxic T cells. In early non-randomized trials, the combination of both agents as sole therapy for metastatic melanoma appeared to be superior to either agent alone (Rosenberg et al, 1989) , although this was not confirmed in a subsequent randomized phase III trial of high-dose intravenous IL-2 with or without IFN-a (Sparano et al, 1993) . The addition of biological therapy with both IL-2 and IFN-a to chemotherapy may prove effective because of the lack of cross-resistance, as the mechanisms of resistance are different between these modes of therapy. Intensive regimens consisting of intravenous IL-2, subcutaneous IFN-a and platinumlDTIC-based chemotherapy have been associated with response rates of 53-55% (Richards et al, 1992; Legha et al, 1993) . Legha et al (1996) treated 30 patients with cisplatin (20 mg m-2 d 2-5), DTIC (800 mg m-2 d 1) and vinblastine (1.6 mg m-2 d 1-5, CVD), followed on days 6-10 and 17-21 by IL-2 continuous i.v. infusion (9 MU m-2 day-') with daily subcutaneous IFN-a (5 MU), repeating after 3 weeks. In a recently reported randomized trial, which compared the sequence of biochemotherapy (i.e. CVD/BIO vs BIO/CVD), they showed a higher response rate with chemotherapy followed by IL-2 (66% vs 40% respectively). In a similar biochemotherapy programme, Richards et al (1992) In our randomized trial, we chose the BCDT regimen as the standard chemotherapy regimen, based on the phase II data available at the time, which suggested this to be the most active regimen (DelPrete et al, 1994) . In view of the severe toxicities experienced by the addition of intravenous IL-2 to chemotherapy (Richards et al, 1992; Legha et al, 1993; Legha et al, 1996) , we elected for a subcutaneous delivery for IL-2. The reduced toxicity and improved tolerability of low-dose subcutaneous IL-2 is well documented (Castello et al, 1993) and has been shown previously to induce clear changes in immunological parameters with a significant rise in NK cells (Azpodien et al, 1993 (Demchak et al, 1991) . In addition, previous investigators have administered infusional IL-2 before DTIC (Stoter et al, 1991) . However, the combination of 3 days subcutaneous moderate-dose IL-2 before chemotherapy followed by 3 days of interferon has not been used in patients with melanoma before.
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Our study was set up befoXre the results of the recent randomized study reporting a superior response rate for chemotherapy followed by biotherapy (Legha et al, 1996 (Rusthoven et al, 1996) . Very few CRs were reported in that trial (< 5%), and none were detected in our chemotherapy-alone group.
There was an increase in some grade 3/4 toxicity in patients who received combined biochemotherapy with BCDT and IL-2/IFN-a, with, in particular, a significantly higher incidence of thrombocytopenia (37% vs 13%). The most obvious non-haematological toxicities included fatigue, flu-like symptoms of fever and chills, and nausea and vomiting. These toxicities are well recognized in patients receiving IL-2 and IFN-a therapy. However, in contrast to the studies of high-dose intravenous IL-2 and subcutaneous IFN-a with chemotherapy (Richards et al, 1992; Legha et al, 1993; Legha et al, 1996) , the severity and incidence of these toxicities was lower in our study.
The importance of dose, route of delivery and schedule for biological therapy remains to be determined. In the adjuvant setting, a clear survival benefit has been reported for high-dose IFN delivered initially at a dose of 20 MU m-2 intravenously every 5 days for 4 weeks, followed by 10 MU m-2 subcutaneously three times a week for 48 weeks (Kirkwood et al, 1996) . Whether the lack of benefit in previous adjuvant studies was related to lower doses of IFN or mode of administration (s.c.) is unclear.
The high response rates in phase II studies of biochemotherapy that use intravenous doses of IL-2 are badly tolerated by patients of poor performance status and bulk tumour burden, and it remains to be seen in a randomized trial whether the benefit of these intensive regimens is real or not. It is possible that, as with renal cell carcinoma, only patients with a minimal tumour will benefit from strategies that include immunotherapy. A recent randomized trial of intravenous IL-2/IFN-a (s.c.) with/without cisplatin demonstrated higher efficacy for combined biochemotherapy (response rate 36% vs 15%, P = 0.01), but failed to show any improvement in progression-free or overall survival (Keilholtz et al, 1996) . If dose is important, then it could be argued that we failed to deliver sufficient biological therapy by the subcutaneous route to have any synergistic effect. This appears unlikely because of evidence of an immunological effect in patients treated with biochemotherapy manifest as overall lymphopenia with a relative increase in the percentage of CD56 NK cells and CD3+/HLADR+ activated T cells (Table 5 ), an effect that was similar to that observed from our previous studies of intra-arterial IL-2 in head and neck cancer (Dadian et al, 1993) .
It remains unclear whether the changes in overall and subset lymphocyte counts represent a compartment phenomenon (subset analysis after IL-2 was finished was not performed), or whether these changes are clinically relevant in terms of an immunological response against the tumour. However, the enhanced toxicity of biochemotherapy compared with chemotherapy alone would indicate that sufficient biotherapy was being administered to have a systemic effect. Furthermore, there are published data suggesting that low-dose IL-2 may be more effective in vivo than higher doses in selectively activating the CD56bright NK subset, which contains high-affinity IL-2 receptors, without activation of monocytes or lymphocytes (Caliguri et al, 1993) . It remains to be determined whether biochemotherapy is more effective than chemotherapy alone in the management of patients with metastatic melanoma. As we initially considered that a 20% improvement in response rate would be necessary to counterbalance any additional toxicity due to the addition of biological therapy, we concluded from this randomized phase II study in which the difference in response rates was 4% (95% CI-17-25%) that a larger phase III study using this regimen was not indicated. Thus, despite a tolerable IL-2/IFN-a biological therapy regimen that resulted in immune activation, little benefit is obtained by including this with conventional BCDT chemotherapy, at the cost of significantly enhanced patient toxicity.
